Indomethacin (Indometacin) sodium 是一种口服有效的COX1/2抑制剂，COX-1 和 COX-2 的IC50值分别为 18 nM 和 26 nM。Indomethacin sodium 具有抗癌和抗感染活性。Indomethacin sodium 可用于癌症、炎症和病毒感染的研究。
| 生物活性 | Indomethacin (Indometacin) sodium is a potent, orally activeCOX1/2inhibitor withIC50values of 18 nM and 26 nM forCOX-1andCOX-2, respectively. Indomethacin sodium has anticancer activity and anti-infective activity. Indomethacin sodium can be used forcancer, inflammation and viralinfectionresearch.[1][2][3]. |
| IC50& Targetsup>[1] | COX-1 18 nM (IC50) | COX-2 26 nM (IC50) |
|
体外研究
(In Vitro) | Indomethacin (Indometacin) sodium (0-150 μM; 24 hours; 3LL-D122 cells) has anticancer activity in vitro[2].
Indomethacin (Indometacin) sodium (0-1000 μM) protects the host cells from damage caused by the virus through activates PKR, resulting in elF2α phosphorylation, and in turn shutting of translation of viral protein and inhibiting replication of the virus (IC50=2μM)[3].
Cell Viability Assay[2] | Cell Line: | 3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells) | | Concentration: | 0, 20, 50, 100 and 150μM | | Incubation Time: | 24 hours | | Result: | Inhibited cell viability at 20 mM, with 50% inhibition at 60 nM. |
Cell Cycle Analysis[2] | Cell Line: | 3LL-D122 cells (highly metastatic variant of mouse LLcarcinoma cells) | | Concentration: | 0, 30 and 80μM | | Incubation Time: | 24 hours | | Result: | Decreased in the percentage of cells at the G2/M phase and increased in the percentage of cells at G1 phase. |
|
体内研究
(In Vivo) | Indomethacin (Indometacin) sodium (0.01-10 mg/kg; p.o.; for 3 hours; male Sprague-Dawley rats) induces paw oedema and hyperalgesmeasurement dose-dependently reversed carrageenan-induced hyperalgesia[1].
Indomethacin (Indometacin) sodium (10 mg/mL; p.o.; daily, for 29 days; male C57BL/6J mice) inhibits tumor growth in vivo[2].
| Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 0.01-10 mg/kg | | Administration: | Oral administration; for 3 hours | | Result: | Inhibited the carrageenan-induced rat paw oedema (ED50=2.0 mg/kg) and hyperalgesia (ED50=1.5 mg/kg) in a dose-dependent manner. |
| Animal Model: | Male C57BL/6J mice[2] | | Dosage: | 10 mg/mL | | Administration: | Oral administration; daily, for 29 days | | Result: | Delayed the onset of tumor growth and the initial growth rate of the footpad tumors. |
|
| Clinical Trial | |
| 分子量 | |
| Formula | |
| CAS 号 | |
| 中文名称 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com